SPEAKER_1: Alright, so last episode we explored the dynamics of neoclouds. Now, let's pivot to a completely different demand driver—government procurement in defense modernization. SPEAKER_2: Right, and that shift matters for how someone tracks a rerating. Defense modernization follows a completely different logic than consumer adoption or enterprise software. The catalyst isn't a product launch or a hyperscaler capex cycle. It's a procurement decision. SPEAKER_1: So walk through the scale first. Because most people's mental model of defense spending is stuck at a fixed number that doesn't change much year to year. SPEAKER_2: That model is outdated. Global military expenditure reached approximately $2.44 trillion in 2023—the steepest annual rise since 2009. Then it climbed further to around $2.72 trillion in 2024, a 9.4% real increase. By 2025, the figure reached roughly $2.9 trillion. That's more than a decade of consecutive growth. SPEAKER_1: Mm-hmm. And the geographic distribution shifted too. SPEAKER_2: Significantly. Between 2015 and 2024, European defense spending rose roughly 83%. In 2024 alone, virtually all European countries increased military budgets—Poland, Germany, Romania, the Netherlands, Sweden all posted double-digit percentage increases. The center of gravity in modernization-driven procurement moved. SPEAKER_1: So not just the U.S. pulling the number higher. Europe is doing real structural rearmament. SPEAKER_2: And NATO as a whole spent about $1.51 trillion in 2024—roughly 55% of global military expenditure. Eighteen of the 32 NATO members met or exceeded the 2% GDP guideline that year, the highest count since that benchmark was adopted in 2014. That's a political commitment converting into procurement contracts. SPEAKER_1: Now, here's the question I want to press on. How does procurement actually function as a rerating catalyst? Because it's not the same as a consumer product going viral or an enterprise software deal closing. SPEAKER_2: [short pause] Think of it this way. When a government commits to a multiyear procurement contract, it creates a demand signal that's legally binding and budget-backed. The U.S. Department of Defense has been using multiyear procurement strategies for key missile systems—AMRAAM, JASSM, LRASM, Standard Missile-6—under what's called a Large Lot Procurement concept. A single contract covering two to five years of purchases. SPEAKER_1: So not annual contracts that could be cancelled or renegotiated every budget cycle. SPEAKER_2: Exactly. For example, under the Large Lot Procurement concept for LRASM in fiscal years 2024 through 2028, the Navy planned a single five-year fixed-price contract for 477 missiles, estimating cost savings of about $129 million—roughly 8.6%. And crucially, those savings get reinvested into additional units rather than returned to the Treasury. The contracting structure itself becomes a force multiplier. SPEAKER_1: Wait—so the procurement design generates more procurement. The efficiency savings buy more missiles. SPEAKER_2: That's the mechanism. And it stabilizes the industrial base in a way that annual contracting never could. Suppliers can justify capacity expansions, new production lines, workforce investments—because the demand signal is locked in for years, not quarters. That's what reprices the companies tied to those production lines. SPEAKER_1: Now, the Russia-Ukraine conflict is clearly the accelerant here. What specifically did it change about procurement priorities? SPEAKER_2: It exposed stockpile inadequacy at scale. Analyses of global defense trends show the conflict accelerated modernization of land-based fires and air defense—artillery, rockets, air-defense interceptors. The FY2023 National Defense Authorization Act granted new authorities for multiyear procurement of high-demand munitions. That's a policy shift from episodic surge buys toward structurally higher baseline production. SPEAKER_1: So the key idea is that the war didn't just increase demand—it changed the procurement architecture. SPEAKER_2: [emphasis] Right. And the Pentagon created an organizational innovation to match: a Joint Production Accelerator Cell, specifically designed to map and de-bottleneck critical production nodes in the munitions supply chain. That's the same logic we applied to CoWoS packaging at TSMC—identify the binding constraint, then direct capital to it. SPEAKER_1: That's a striking parallel. The Pentagon running a bottleneck analysis on its own supply chain. SPEAKER_2: And it matters for investors tracking this series. Modern defense procurement strategies now explicitly link spending to readiness and supply-chain resilience. The firms that benefit aren't necessarily the largest prime contractors. They're the ones that can scale production quickly and integrate across platforms—sensors, munitions, command-and-control systems. SPEAKER_1: So how does someone distinguish a real defense-tech rerating from a company that just attracted attention because defense spending headlines were everywhere? SPEAKER_2: The metrics that matter are awarded contracts, funded backlog, revenue recognition, and production scale. Investor attention before government revenue is large can be justified—but it's also where the risk lives. A company can attract capital on the promise of a procurement win that then gets delayed, descoped, or cancelled. Failed tests, budget changes, political shifts—those are the failure modes specific to this sector. SPEAKER_1: And there's a legislative layer that most people miss. Multiyear contracts above a certain threshold still require congressional sign-off. SPEAKER_2: Correct. Multiyear munitions contracts above a $500 million threshold require specific congressional appropriator approval. So industrial-base modernization through procurement stays tightly coupled to legislative oversight. That's a risk that doesn't exist in enterprise software or consumer hardware. A procurement win can be real and still get delayed by a budget resolution. SPEAKER_1: The takeaway for someone following this chain: defense modernization shows a rerating mechanism that's entirely different from everything else in this series. No consumer adoption curve, no hyperscaler capex cycle. A new buyer—government—with a new mission can reset valuations for companies tied to drones, autonomy, sensors, munitions, and modern battlefield systems. SPEAKER_2: And that broadens the framework beyond AI entirely. The same six questions apply—what did the market believe before, what changed, when did the rerating happen, how large was the move, who benefited next, what may still be underpriced—but here, the catalyst is government procurement, not product adoption. In the next episode, we'll explore how biotech platform optionality, specifically Moderna and mRNA oncology, demonstrates a rerating based on future potential rather than current revenue. SPEAKER_1: And that prime-versus-challenger distinction is worth pressing on before we close. Because someone tracking this series might assume the obvious winners are the large established contractors. But that's not necessarily where the rerating lives. SPEAKER_2: Right. Think of it this way—prime contractors like Lockheed or Raytheon have enormous revenue bases, stable margins, and long contract cycles. They benefit from modernization, but their valuations already reflect a lot of that. The rerating opportunity tends to sit with newer defense-technology firms: drone manufacturers, autonomy software companies, sensor integrators, data platforms built for the battlefield. SPEAKER_1: So not the company building the aircraft carrier. The company building the targeting software that runs on it. SPEAKER_2: Exactly. And those firms can attract significant investor attention before government revenue becomes large—because the market is pricing the option on a procurement win. That's the counterintuitive part. But it's also where the risk concentrates. SPEAKER_1: Wait—so the same dynamic that made neoclouds interesting before their AI cloud revenue was large applies here too? SPEAKER_2: [short pause] Same structure, different sector. A company can rerate on the expectation of a contract award that then gets delayed, descoped, or cancelled. Failed operational tests, budget resolutions that slip, political shifts in procurement priorities—those are the failure modes specific to defense tech. And the legislative layer adds another friction point that doesn't exist in enterprise software. SPEAKER_1: The $500 million threshold requiring congressional sign-off. SPEAKER_2: Correct. Multiyear munitions contracts above that level need specific appropriator approval. So a procurement win can be real—announced, contracted in principle—and still get delayed by a budget resolution or a change in committee priorities. That's a risk profile most investors in consumer or enterprise tech have never had to model. SPEAKER_1: Mm-hmm. So for someone tracking this as an investment signal—what are the metrics that actually confirm procurement interest is converting into business value? Not just headlines. SPEAKER_2: awarded contracts, funded backlog, revenue recognition, production scale, gross margin, and renewal or expansion rates. Funded backlog is the most important early signal—it means the money is appropriated, not just authorized. A company with a large unfunded pipeline is a different risk than one with funded orders in hand. SPEAKER_1: And the geographic spread of this modernization matters too. Because the demand signal isn't coming from one buyer. SPEAKER_2: That's the key idea for someone tracking the global picture. SIPRI data shows the world's 15 largest military spenders all increased expenditure in 2024—but the steepest relative growth was in European and Middle Eastern states, not the U.S. or China. The center of gravity in modernization-driven procurement has shifted geographically. That means the addressable market for defense-tech firms is genuinely global, not just Pentagon-dependent. SPEAKER_1: And Europe's structural rearmament is worth naming explicitly. An 83% increase in European defense spending between 2015 and 2024—that's not a one-year budget bump. SPEAKER_2: [emphasis] It's a decade-long structural shift. And EU countries collectively drove about half of the net positive contribution to global military expenditure expansion in 2025. For a defense-tech firm with NATO-compatible systems, that's a second procurement market running in parallel with the U.S. cycle—and on a different budget timeline, which actually reduces concentration risk. SPEAKER_1: So the takeaway from this episode, for someone following the full chain: defense modernization shows a rerating mechanism that's structurally different from everything else in this series. The catalyst isn't consumer adoption or hyperscaler capex. It's a new buyer—government—with a new mission, committing capital through legally binding, multi-year contracts. SPEAKER_2: And that broadens the framework the series has been building. The same six questions apply—what did the market believe before, what changed, when did the rerating happen, how large was the move, who benefited next, what may still be underpriced—but the demand signal is procurement, not product adoption. The firms that benefit are the ones that can scale production quickly, integrate across platforms, and survive the legislative friction that comes with every large contract. Now, the series moves to a sector where the rerating logic shifts again—and in a direction that surprises most people. Moderna and mRNA oncology show what happens when a technology platform gets repriced not on current revenue, but on what it might become. That's the next episode.